A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen Therapy

Trial Profile

A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Aug 2018

At a glance

  • Drugs HPN 424 (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Harpoon Therapeutics
  • Most Recent Events

    • 30 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 22 Jun 2018 Status changed from planning to not yet recruiting.
    • 25 May 2017 According to a Harpoon Therapeutics media release, the company expects to enter phase I clinical trials in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top